Opinion|Videos|September 27, 2024
Overview of RedirecTT-1, MagnetisMM-30 and MagnetisMM-5
Noopur Raje, MD, reviews clinical research on elranatamab combination therapy in patients with relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Please comment on the clinical trials evaluating combination strategies with bispecifics:
- Talquetamab
- RedirecTT-1
- Elranatamab
- MagnetisMM-30
- MagnetisMM-5
Advertisement
Related to this article
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
Matthew J. Frigault, MD, and Adam D. Cohen, MD, discuss guidelines, 5-year data, sequencing, and referral practice for cellular therapy in multiple myeloma.
Experts highlight updated findings from CARTITUDE-2, how to mitigate late toxicities, and other key considerations in the modern multiple myeloma landscape.
Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.
Ralph V. Boccia, MD, FACP, explained how community practices can build the workflow and capacity to deliver bispecific step-up dosing in an outpatient setting.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Talazoparib/Enzalutamide for HRR Gene-Altered Metastatic Prostate Cancer
2
Ivonescimab Combo Improves Survival in Advanced Biliary Tract Cancer
3
Exploring The Use of GLP-1 Receptor Agonists in Breast Cancer Care
4
Sac-TMT Improves Survival vs Chemotherapy in Pretreated Endometrial Cancer
5